248 related articles for article (PubMed ID: 17296739)
1. Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients.
Pellegrin I; Breilh D; Coureau G; Boucher S; Neau D; Merel P; Lacoste D; Fleury H; Saux MC; Pellegrin JL; Lazaro E; Dabis F; Thiébaut R;
Antimicrob Agents Chemother; 2007 Apr; 51(4):1473-80. PubMed ID: 17296739
[TBL] [Abstract][Full Text] [Related]
2. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
Pellegrin I; Breilh D; Ragnaud JM; Boucher S; Neau D; Fleury H; Schrive MH; Saux MC; Pellegrin JL; Lazaro E; Vray M
Antivir Ther; 2006; 11(4):421-9. PubMed ID: 16856615
[TBL] [Abstract][Full Text] [Related]
3. Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).
Pellegrin I; Wittkop L; Joubert LM; Neau D; Bollens D; Bonarek M; Girard PM; Fleury H; Winters B; Saux MC; Pellegrin JL; Thiébaut R; Breilh D;
Antivir Ther; 2008; 13(2):271-9. PubMed ID: 18505178
[TBL] [Abstract][Full Text] [Related]
4. Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.
Masquelier B; Assoumou KL; Descamps D; Bocket L; Cottalorda J; Ruffault A; Marcelin AG; Morand-Joubert L; Tamalet C; Charpentier C; Peytavin G; Antoun Z; Brun-Vézinet F; Costagliola D;
J Antimicrob Chemother; 2008 Jun; 61(6):1362-8. PubMed ID: 18390885
[TBL] [Abstract][Full Text] [Related]
5. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
Marcelin AG; Flandre P; Molina JM; Katlama C; Yeni P; Raffi F; Antoun Z; Ait-Khaled M; Calvez V
Antimicrob Agents Chemother; 2008 Dec; 52(12):4251-7. PubMed ID: 18852278
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.
von Hentig N; Babacan E; Staszewski S; Stürmer M; Doerr HW; Lötsch J
Antivir Ther; 2007; 12(8):1237-46. PubMed ID: 18240863
[TBL] [Abstract][Full Text] [Related]
7. Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
Marcelin AG; Affolabi D; Lamotte C; Mohand HA; Delaugerre C; Wirden M; Voujon D; Bossi P; Ktorza N; Bricaire F; Costagliola D; Katlama C; Peytavin G; Calvez V
J Med Virol; 2004 Sep; 74(1):16-20. PubMed ID: 15258963
[TBL] [Abstract][Full Text] [Related]
8. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
Arvieux C; Tribut O
Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
[TBL] [Abstract][Full Text] [Related]
9. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
[TBL] [Abstract][Full Text] [Related]
10. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
Raguin G; Chêne G; Morand-Joubert L; Taburet AM; Droz C; Le Tiec C; Clavel F; Girard PM;
Antivir Ther; 2004 Aug; 9(4):615-25. PubMed ID: 15456093
[TBL] [Abstract][Full Text] [Related]
11. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
[TBL] [Abstract][Full Text] [Related]
12. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
[TBL] [Abstract][Full Text] [Related]
13. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Maillard A; Chapplain JM; Tribut O; Bentué-Ferrer D; Tattevin P; Arvieux C; Michelet C; Ruffault A
J Clin Virol; 2007 Feb; 38(2):131-8. PubMed ID: 17208042
[TBL] [Abstract][Full Text] [Related]
14. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Lazzarin A; Castagna A
J Med Virol; 2006 Dec; 78(12):1537-41. PubMed ID: 17063520
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
16. Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.
De Luca A; Di Giambenedetto S; Maserati R; Gianotti N; Narciso P; Antinori A; Di Perri G; Prosperi MC; Baldanti F; Micheli V; Zazzi M; Perno CF; Santoro MM; ;
Antivir Ther; 2011; 16(4):489-97. PubMed ID: 21685536
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients.
Clevenbergh P; Boulmé R; Kirstetter M; Dellamonica P
HIV Med; 2004 Jul; 5(4):284-8. PubMed ID: 15236618
[TBL] [Abstract][Full Text] [Related]
18. Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Marcelin AG; Dalban C; Peytavin G; Lamotte C; Agher R; Delaugerre C; Wirden M; Conan F; Dantin S; Katlama C; Costagliola D; Calvez V
Antimicrob Agents Chemother; 2004 Dec; 48(12):4687-92. PubMed ID: 15561845
[TBL] [Abstract][Full Text] [Related]
19. Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.
Descamps D; Lambert-Niclot S; Marcelin AG; Peytavin G; Roquebert B; Katlama C; Yeni P; Felices M; Calvez V; Brun-Vézinet F
J Antimicrob Chemother; 2009 Mar; 63(3):585-92. PubMed ID: 19147519
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.
Valer L; de Mendoza C; Soriano V
J Med Virol; 2005 Dec; 77(4):460-4. PubMed ID: 16254964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
